Review



il7  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Miltenyi Biotec il7
    Il7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/MACS+GMP+Recombinant+Human+IL-7/us12698315-687-29-30
    Average 93 stars, based on 23 article reviews
    il7 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Purification:

    Article Title: In vivo site-specific engineering to reprogram T cells
    Article Snippet: .. After thawing, T lymphocytes were purified using the EasySep Human T cell isolation kit (StemCell Technologies, 17951) and activated with Dynabeads Human T Expander CD3/CD28 at a 1:1 bead-to-cell ratio (Gibco, 11141D) in X-VIVO 15 medium (Lonza, BP04-744Q) supplemented with human serum (5%, Gemini Bioproducts, 100-512), IL-7 (5 ng ml −1 , Miltenyi Biotec, 130-095-367) and IL-15 (5 ng ml −1 , Miltenyi Biotec, 130-095-760) at a density of 1 × 10 6 cells per ml. ..

    Article Title: Combined talimogene laherparepvec and binimetinib in patients with NRAS -mutated melanoma induces anti-tumor immunity
    Article Snippet: For viral packaging, Lenti-X 293T cells (Takara, 632180) were transfected using VSV-G Single Shots (Takara, 631282), then 48 h supernatants were collected, concentrated with Lenti-X Concentrator (Takara, 631231) per manufacturer’s protocols, and used without freezing. .. Human CD8 + T cells were purified from PBMCs by magnetic negative selection (StemCell, 17953) and activated for 48 h in complete RPMI (cRPMI) containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1× non-essential amino acids, and 100 U/mL penicillin-streptomycin supplemented with 25 ng/mL IL-7 (Miltenyi, 130-095-367), 50 ng/mL IL-15 (Miltenyi, 130-095-760), and TransAct anti-CD3/CD28 reagent (Miltenyi, 130-128-758). ..

    Cell Isolation:

    Article Title: In vivo site-specific engineering to reprogram T cells
    Article Snippet: .. After thawing, T lymphocytes were purified using the EasySep Human T cell isolation kit (StemCell Technologies, 17951) and activated with Dynabeads Human T Expander CD3/CD28 at a 1:1 bead-to-cell ratio (Gibco, 11141D) in X-VIVO 15 medium (Lonza, BP04-744Q) supplemented with human serum (5%, Gemini Bioproducts, 100-512), IL-7 (5 ng ml −1 , Miltenyi Biotec, 130-095-367) and IL-15 (5 ng ml −1 , Miltenyi Biotec, 130-095-760) at a density of 1 × 10 6 cells per ml. ..

    Irradiation:

    Article Title: Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses.
    Article Snippet: .. For alloreactive T cell MLR assays, unedited graft donor T cells were irradiated at 30 Gy and co-cultured with host PBMCs at a ratio of 1:1 in RPMI supplemented with 10% FBS and 20 IU/mL of recombinant human IL-2, IL-7 (Miltenyi Biotec, 130-093-937), and IL-15 (Miltenyi Biotec, 130-093-955). ..

    Recombinant:

    Article Title: Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses.
    Article Snippet: .. For alloreactive T cell MLR assays, unedited graft donor T cells were irradiated at 30 Gy and co-cultured with host PBMCs at a ratio of 1:1 in RPMI supplemented with 10% FBS and 20 IU/mL of recombinant human IL-2, IL-7 (Miltenyi Biotec, 130-093-937), and IL-15 (Miltenyi Biotec, 130-093-955). ..

    Cell Culture:

    Article Title: Method for gene transfer into gamma-delta type T cell
    Article Snippet: .. The monocytes adjusted to 1.5×106 cells/mL with the culture solution of Yssel containing 10% human AB serum were cultured for one day in the presence of tetrakispivaloyloxymethyl 2-(thiazole-2-ylamino) ethylidene-1,1-bisphosphonate (compound 7, 1 μM), and then added with 25 ng/mL of IL-7 (Miltenyi Biotec, catalog number: 170-076-111) and 25 ng/mL of IL-15 (Miltenyi Biotec, catalog number: 170-076-114), and further cultured for 10 days. .. The frequency of the γδT cells in the monocyte population were analyzed by flow cytometry (FACSCANTO II, Becton Dickinson).

    Selection:

    Article Title: Combined talimogene laherparepvec and binimetinib in patients with NRAS -mutated melanoma induces anti-tumor immunity
    Article Snippet: For viral packaging, Lenti-X 293T cells (Takara, 632180) were transfected using VSV-G Single Shots (Takara, 631282), then 48 h supernatants were collected, concentrated with Lenti-X Concentrator (Takara, 631231) per manufacturer’s protocols, and used without freezing. .. Human CD8 + T cells were purified from PBMCs by magnetic negative selection (StemCell, 17953) and activated for 48 h in complete RPMI (cRPMI) containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1× non-essential amino acids, and 100 U/mL penicillin-streptomycin supplemented with 25 ng/mL IL-7 (Miltenyi, 130-095-367), 50 ng/mL IL-15 (Miltenyi, 130-095-760), and TransAct anti-CD3/CD28 reagent (Miltenyi, 130-128-758). ..

    Electroporation:

    Article Title: Targeting ZC3H12C improves T cell persistence and antitumor function in adoptive T cell therapy
    Article Snippet: .. Electroporation was performed using program CA137, and cells were subsequently recovered in complete medium containing 25 IU/ml IL-7 (Miltenyi Biotec 130-095-367) and 50 IU/ml IL-15 (Miltenyi Biotec 130-095-760) for 3 days prior to downstream analyses. .. CD8 + T cells were activated using TransAct (1:100; Miltenyi Biotec, 130-111-160) in the presence of recombinant human IL-2 (100 IU/ml; Proleukin S, Novartis).

    Article Title: Ultra-large targeted DNA integrations in primary human cells
    Article Snippet: .. For electroporation experiments performed on the Xenon and Maxcyte, CD3+ T cells were activated with CTS Dynabeads CD3/CD28 at a 1:1 bead to cell ratio with 20U/mL of IL-7 (Miltenyi Biotec, 170-076-114) and 100U/mL IL-15 (Miltenyi Biotec, 170-076-111) in tissue culture flasks. .. Following electroporation, cells were cultured at approximately 2e6 cells/mL and expanded in gas-permeable G-Rex culture vessels (Wilson Wolf, 80192M, 80240M, 80660M, RU81100) in TheraPeak X-VIVO 15 (Lonza, BP04-744Q) supplemented with 5% human AB serum (Access Cell Culture, 516-HI GI), 20U/mL of IL-7, and 100U/mL IL-15 for a 7-day expansion.



    Similar Products

    93
    Miltenyi Biotec il7
    Il7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/MACS+GMP+Recombinant+Human+IL-7/us12698315-687-29-30
    Average 93 stars, based on 1 article reviews
    il7 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Bio-Techne corporation recombinant mouse il-7 protein
    Recombinant Mouse Il 7 Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Recombinant+Mouse+IL-7+Protein/bio-techne+corporation___407-ml
    Average 95 stars, based on 1 article reviews
    recombinant mouse il-7 protein - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    92
    Miltenyi Biotec mouse il-7, research grade
    Mouse Il 7, Research Grade, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Mouse+IL-7%2C+research+grade/custom%40130-094-636%4010%2E64898%2F2026%2E07%2E25%2E740527
    Average 92 stars, based on 1 article reviews
    mouse il-7, research grade - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec recombinant human flt3 ligand miltenyi biotec
    Recombinant Human Flt3 Ligand Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Human+IL-7%2C+research+grade/pm42486103-554-30-33
    Average 96 stars, based on 1 article reviews
    recombinant human flt3 ligand miltenyi biotec - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec human 686 il 7
    Human 686 Il 7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Human+IL-7%2C+premium+grade/pm42478044-266-28-33
    Average 96 stars, based on 1 article reviews
    human 686 il 7 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec human il 7
    (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured <t>under</t> <t>IL-7</t> maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).
    Human Il 7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Human+IL-7%2C+premium+grade/bio_rxiv__64898__2026__06__26__734763-199-16-20
    Average 96 stars, based on 1 article reviews
    human il 7 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Yeasen Biotechnology il 7
    (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured <t>under</t> <t>IL-7</t> maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).
    Il 7, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/7+il/pm42321078-332-16-17
    Average 86 stars, based on 1 article reviews
    il 7 - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    95
    R&D Systems hil 7
    (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured <t>under</t> <t>IL-7</t> maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).
    Hil 7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Recombinant+Mouse+IL-7+Protein/pmc13059316-49-29-30
    Average 95 stars, based on 1 article reviews
    hil 7 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec interleukin 7
    (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured <t>under</t> <t>IL-7</t> maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).
    Interleukin 7, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/il+7/Human+IL-7%2C+premium+grade/pm42218123-558-28-33
    Average 96 stars, based on 1 article reviews
    interleukin 7 - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured under IL-7 maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).

    Journal: bioRxiv

    Article Title: Bidirectional modulation of aging-associated cellular phenotypes by mitochondrial genome replacement

    doi: 10.64898/2026.06.26.734763

    Figure Lengend Snippet: (A) mtDNA heteroplasmy in MirT cells on day 5, determined by TaqMan SNP assays. (B) Time course of mitochondrial heteroplasmy following MirT cells generation (n = 3). (C) Correlation between reduction of endogenous mtDNA copy number and donor mtDNA incorporation efficiency. (D) Schematic overview of the adoptive cell transfer (ACT) experiments using OT-1 T cells in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Created with BioRender.com. (E) Representative OCR traces of Young, Aged, and MirT cells-treated T cells cultured under IL-7 maintenance conditions for 5 days following the MirT cells generation protocol. (F) Quantification of spare respiratory capacity (SRC), proton leak, ATP production (G) OCR/ECAR metabolic profiles derived from the OCR and ECAR analyses shown in panel F. (H) Determination of the number of aged OT-1 T cells required to suppress tumor growth following ACT (n = 3–4). (I) Tumor growth following ACT using young or aged OT-1 T cells in combination with anti-PD-L1 antibody (n = 3–4). (J) Comparison of antitumor activity between young OT-1 T cells, aged OT-1 T cells, and MirT cells following ACT in MC38 tumor-bearing mice treated with anti-PD-L1 antibody. Data are presented as mean ± SD in (E) and mean ± SEM in (H–K). P values were determined using one-way ANOVA followed by Tukey’s multiple-comparison test (F) or two-way mixed-design ANOVA followed by Tukey’s multiple-comparison test (J).

    Article Snippet: For LNP transfection, T cells were pre-activated for 1 day in TexMACS medium supplemented with recombinant human IL-7 (20 ng/mL; Miltenyi Biotec, 130-095-362) and CD3/CD28 DynabeadsTM (Gibco, 11453D).

    Techniques: Cell Culture, Derivative Assay, Comparison, Activity Assay